Horizon Therapeutics (NASDAQ:HZNP) had its target price lifted by analysts at Cantor Fitzgerald from $32.00 to $36.00 in a research report issued on Friday, The Fly reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 22.03% from the company’s previous close.
HZNP has been the subject of several other research reports. Piper Jaffray Companies set a $33.00 price target on shares of Horizon Therapeutics and gave the company a “buy” rating in a report on Monday, August 26th. Zacks Investment Research lowered shares of Horizon Therapeutics from a “buy” rating to a “hold” rating and set a $31.00 price target for the company. in a report on Tuesday, October 29th. Bank of America started coverage on shares of Horizon Therapeutics in a report on Thursday, September 26th. They issued a “buy” rating and a $34.00 price target for the company. ValuEngine lowered shares of Horizon Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 5th. Finally, Guggenheim started coverage on shares of Horizon Therapeutics in a report on Thursday, September 12th. They issued a “buy” rating and a $36.00 price target for the company. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $33.77.
Shares of HZNP traded down $0.15 on Friday, hitting $29.50. The company’s stock had a trading volume of 1,544,700 shares, compared to its average volume of 1,697,509. The company has a 50 day moving average price of $27.81 and a 200 day moving average price of $25.97. The company has a market capitalization of $5.57 billion, a PE ratio of 16.12, a PEG ratio of 1.76 and a beta of 0.83. Horizon Therapeutics has a fifty-two week low of $17.94 and a fifty-two week high of $31.25. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.20 and a quick ratio of 2.12.
In related news, EVP Irina Konstantinovsky sold 17,838 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $26.70, for a total value of $476,274.60. Following the completion of the transaction, the executive vice president now directly owns 44,819 shares of the company’s stock, valued at approximately $1,196,667.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James Samuel Shannon sold 15,500 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $26.59, for a total transaction of $412,145.00. Following the completion of the transaction, the director now directly owns 15,500 shares of the company’s stock, valued at $412,145. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 576,405 shares of company stock valued at $16,126,099. Company insiders own 4.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. First Mercantile Trust Co. boosted its stake in shares of Horizon Therapeutics by 31.6% during the 2nd quarter. First Mercantile Trust Co. now owns 10,803 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 2,597 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in Horizon Therapeutics by 4.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 218,129 shares of the biopharmaceutical company’s stock valued at $5,248,000 after acquiring an additional 8,999 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Horizon Therapeutics in the 2nd quarter valued at about $331,000. Point72 Asset Management L.P. bought a new position in Horizon Therapeutics in the 2nd quarter valued at about $125,000. Finally, Bowling Portfolio Management LLC bought a new position in Horizon Therapeutics in the 2nd quarter valued at about $494,000. 86.70% of the stock is owned by hedge funds and other institutional investors.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Recommended Story: What is a good dividend yield?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.